MAIA Biotechnology

Yahoo Finance • 9 days ago

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO , Nov. 21, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYS... Full story

Yahoo Finance • last month

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-sta... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology announces $0.74M private placement

* MAIA Biotechnology (NYSE:MAIA) announced [https://seekingalpha.com/pr/20263719-maia-biotechnology-announces-736600-private-placement] that it has entered into definitive agreements for the purchase and sale of an aggregate of 0.60M sha... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology Announces $736,600 Private Placement

CHICAGO, IL, Oct. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it ha... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets

MAIA’s Board of Directors authorizes holdings of up to 90% of the Company’s liquid assets in cryptocurrencies (BTC), Ethereum (ETH), and USD Coin (USDC) CHICAGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American:... Full story

Yahoo Finance • 2 months ago

Monday 10/6 Insider Buying Report: KMX, MAIA

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is th... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology announces $2.25 million private placement

* MAIA Biotechnology (NYSE:MAIA [https://seekingalpha.com/symbol/MAIA]) announced on Monday that it has entered into definitive agreements for the purchase and sale of an aggregate of 1.74 million shares of common stock at $1.30 per shar... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology Announces $2.25 Million Private Placement

CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it h... Full story

Yahoo Finance • 2 months ago

Simpson Manufacturing is Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals a... Full story

Yahoo Finance • 2 months ago

MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NY... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted p... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that... Full story

Yahoo Finance • 4 months ago

MAIA Biotechnology Reports FDA's Fast Track Designation For Ateganosine

(RTTNews) - MAIA Biotechnology (MAIA) announced that the FDA has granted Fast Track designation for ateganosine for the treatment of non-small cell lung cancer. Ateganosine is currently being evaluated in a Phase 2 THIO-101 clinical trial... Full story

Yahoo Finance • 4 months ago

MAIA Biotechnology's 41% decline validates InvestingPro's overvalued call

When InvestingPro’s Fair Value model flagged MAIA Biotechnology (NYSE:MAIA) as overvalued in April 2024, the clinical-stage biotechnology company was trading at $2.90. Today, the stock trades at $1.69, validating the model’s assessment wit... Full story

Yahoo Finance • 5 months ago

Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners

Maia Biotechnology, Inc. (NYSE American:MAIA), a biotechnology company with a market capitalization of $52.7 million, announced it has entered into a stock purchase agreement with Prevail Partners, LLC to issue and sell up to $587,905 of i... Full story

Yahoo Finance • 5 months ago

MAIA Biotechnology appoints HCC experts to scientific advisory board

CHICAGO - MAIA Biotechnology, Inc. (NYSE American:MAIA), a $52.43 million market cap biotechnology company currently trading at $1.73 per share, has appointed two oncologists specializing in hepatocellular carcinoma (HCC) to its Scientific... Full story

Yahoo Finance • 5 months ago

MAIA Biotechnology, Roche sign supply agreement for cancer therapies

MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roch... Full story

Yahoo Finance • 3 years ago

Sidoti's January Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. The links can a... Full story